MICHAEL KESSELRING: Open Payments
NPI 1033518543 · FAIRLAWN, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$786 in 22 payments from 7 companies in 2025. Trend: 2023 $1,462 · 2024 $1,061 · 2025 $786
Food & beverage: $786
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 2 | $246 |
| Otsuka America Pharmaceutical, Inc. | 8 | $177 |
| Supernus Pharmaceuticals, Inc. | 5 | $144 |
| Axsome Therapeutics, Inc. | 1 | $124 |
| ABBVIE INC. | 4 | $57 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| TMS NeuroHealth Centers Inc. | 1 | $18 |
Products named: INGREZZA, REXULTI, Qelbree, Auvelity, VRAYLAR, TMS NeuroHealth Centers Inc..
Industry payments across OH — which companies pay providers there.
